Generic Name
Melphalan
Brand Names
IVRA, Hepzato, Evomela
FDA approval date: January 10, 2013
Classification: Alkylating Drug
Form: Injection, Kit
What is IVRA (Melphalan)?
Multiple Myeloma-Palliative Treatment IVRA is indicated for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate. IVRA is an alkylating drug indicated for palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate.
Approved To Treat
Top Global Experts
There are no experts for this drug
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
There is no clinical trials being done for this treatment
Related Latest Advances
There is no latest advances for this treatment